Drug intelligence / Profile preview

CL-NK-001

Development stage: Phase 1
Lead developer: Changhai Hospital
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CL-NK-001 is a CAR-NK cell therapy being investigated for the treatment of advanced pancreatic cancer. It is currently in early clinical development, with a Phase 1 first-in-human, dose-escalation study initiated in February 2025. The therapy represents an innovative approach in the field of natural killer cell-based immunotherapies for solid tumors.

Beyond the preview

Go deeper on CL-NK-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-NK-001.

Explore the full profile